COVID-19 vaccines

Government of Canada funds five new projects to encourage COVID-19 vaccination in Canada

Retrieved on: 
Monday, July 12, 2021
COVID-19, COVID-19 vaccines, Clinical trials, Medicine, Vaccines, RNA vaccines, Medical research, BioNTech, Pfizer–BioNTech COVID-19 vaccine, Vaccination, COVID-19 vaccine, Vaccine

This project will provide credible COVID-19 vaccine information to these communities and deliver low-barrier vaccine clinics and mobile services.

Key Points: 
  • This project will provide credible COVID-19 vaccine information to these communities and deliver low-barrier vaccine clinics and mobile services.
  • This project will provide COVID-19 testing and vaccine education, promotion, and outreach to facilitate and encourage vaccine uptake among these populations.
  • In 2020, as a response to Canada's COVID-19 vaccination efforts and building on the early momentum of the IPF, the Government of Canada invested an additional $64 million for projects to support COVID-19 vaccine uptake in Canada.
  • Regina Treaty/Status Indian Services Inc. will receive up to $100,000 for its project, Regina Urban Indigenous COVID-19 Vaccination Strategy.

Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine

Retrieved on: 
Monday, July 12, 2021
Science, Research, Pharmaceutical, Medical Supplies, General Health, Health, Infectious diseases, Clinical trials, COVID-19, COVID-19 vaccines, Clinical trials, Medicine, Vaccines, Medical research, RNA vaccines, BioNTech, Moderna COVID-19 vaccine, Pfizer–BioNTech COVID-19 vaccine, COVID-19 vaccine, Moderna, the COVID-19 Vaccine Moderna, Moderna, THE COVID-19 VACCINE MODERNA, MODERNA

We appreciate the support from the government of Argentina with this supply agreement for doses of the Moderna COVID-19 vaccine or our variant booster candidates, said Stphane Bancel, Chief Executive Officer of Moderna.

Key Points: 
  • We appreciate the support from the government of Argentina with this supply agreement for doses of the Moderna COVID-19 vaccine or our variant booster candidates, said Stphane Bancel, Chief Executive Officer of Moderna.
  • We are committed to making our vaccine available around the world as we seek to address the pandemic with our COVID-19 vaccine.
  • The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein.
  • Moderna has filed for emergency (or other conditional, interim or provisional) authorization for use of its COVID-19 vaccine in adolescents with global health agencies.

Sputnik V vaccine elicits high IGG antibodies and neutralizing antibodies titers, a study in Argentina published in international Cell Reports Medicine journal shows

Retrieved on: 
Monday, July 12, 2021
COVID-19 vaccines, Vaccines, Clinical trials, Vaccination, Medicine, COVID-19 pandemic in Russia, Science and technology in Russia, Gamaleya Research Institute of Epidemiology and Microbiology, Sputnik V COVID-19 vaccine, Sputnik Light, COVID-19, Immunoglobulin G

The study has been published in an international peer-reviewed, open access Cell Reports Medicine journal: https://www.sciencedirect.com/science/article/pii/S2666379121002081

Key Points: 
  • The study has been published in an international peer-reviewed, open access Cell Reports Medicine journal: https://www.sciencedirect.com/science/article/pii/S2666379121002081
    The research evaluates SARS-CoV-2-specific antibody responses after vaccination of 288 healthcare workers with Sputnik V in Argentina, measuring IgG anti-spike titers and neutralizing capacity after one and two doses among non-infected and previously infected individuals.
  • Among key findings in the article they note that the first dose of Sputnik V induced strong immune response in 94% of individuals previously not infected with COVID.
  • In authors' opinion, vaccination with only the first component of Sputnik V (Sputnik Light vaccine) is sufficient to protect previously infected individuals.
  • To date, Sputnik V has been registered in 67 countries globally with a total population of over 3.5 billion people.

Aimmune to Present New Two-Year Treatment Satisfaction Data From Patients With Peanut Allergy at EAACI Hybrid Annual Congress 2021

Retrieved on: 
Friday, July 9, 2021
Health, Fitness & Nutrition, Other Science, Clinical trials, Science, Pharmaceutical, Biotechnology, Health sciences, Health, Medicine, Clinical research, Clinical trials, COVID-19 vaccines, Medical research, Pharmaceutical industry, COVID-19 vaccine, Placebo, PALFORZIA, Aimmune, Nestlé Health Science, PALFORZIA, AIMMUNE, NESTLé HEALTH SCIENCE

The company will share updated treatment satisfaction data evaluated in its Phase 3, randomised, double-blind, placebo-controlled trial, PALISADE, and open-label follow-on trial, ARC004.

Key Points: 
  • The company will share updated treatment satisfaction data evaluated in its Phase 3, randomised, double-blind, placebo-controlled trial, PALISADE, and open-label follow-on trial, ARC004.
  • Patient-reported treatment satisfaction was evaluated over two years following daily treatment with PALFORZIA in a clinical trial setting using the Treatment Satisfaction Questionnaire for Medication (TSQM-9).
  • Peanut allergic participants reported overall satisfaction with the effectiveness and convenience items, as well as the medications ability to treat their condition.
  • Additional data to be presented at EAACI include an update on the ongoing Phase 3 ARC008 open-label study which is looks at longer-term safety in patients.

Ortho Clinical Diagnostics' Quantitative COVID-19 IgG Antibody Test First to Receive FDA Emergency Use Authorization

Retrieved on: 
Friday, July 9, 2021
Medical specialties, Virology, Medicine, Health, COVID-19, Occupational safety and health, Public health, Zoonoses, Spike protein, COVID-19 vaccines, CIGA Healthcare, Abingdon Health

Ortho's new quantitative COVID-19 IgG antibody test targets the S1 spike protein and is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2.

Key Points: 
  • Ortho's new quantitative COVID-19 IgG antibody test targets the S1 spike protein and is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2.
  • "The development of the VITROS Anti-SARS-CoV-2 IgG Quantitative Test shows Ortho's leadership in response to the need for standardization of SARS-CoV-2 serological methods currently used," said Ivan Salgo, MD, head of medical, clinical, and scientific affairs, Ortho Clinical Diagnostics.
  • "Ortho's quantitative COVID-19 IgG antibody test, which targets the spike protein, is an important tool to help health care and policy teams to understand long-term antibody responses to SARS-CoV-2."
  • The VITROS COVID-19 antibody tests include IgG and Total tests that target the S1 spike protein, and a Total test that targets the nucleocapsid protein.

Ortho Clinical Diagnostics' Quantitative COVID-19 IgG Antibody Test First to Receive FDA Emergency Use Authorization

Retrieved on: 
Friday, July 9, 2021
Medical specialties, Virology, Medicine, Health, COVID-19, Occupational safety and health, Public health, Zoonoses, Spike protein, COVID-19 vaccines, CIGA Healthcare, Abingdon Health

Ortho's new quantitative COVID-19 IgG antibody test targets the S1 spike protein and is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2.

Key Points: 
  • Ortho's new quantitative COVID-19 IgG antibody test targets the S1 spike protein and is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2.
  • "The development of the VITROS Anti-SARS-CoV-2 IgG Quantitative Test shows Ortho's leadership in response to the need for standardization of SARS-CoV-2 serological methods currently used," said Ivan Salgo, MD, head of medical, clinical, and scientific affairs, Ortho Clinical Diagnostics.
  • "Ortho's quantitative COVID-19 IgG antibody test, which targets the spike protein, is an important tool to help health care and policy teams to understand long-term antibody responses to SARS-CoV-2."
  • The VITROS COVID-19 antibody tests include IgG and Total tests that target the S1 spike protein, and a Total test that targets the nucleocapsid protein.

Avance Clinical Congratulates Client Tetherex Pharmaceuticals on Initiation of Dosing in a Phase 1 Clinical Study Using a Novel Single-Cycle Adenovirus Vaccine Strategy in Australia

Retrieved on: 
Friday, July 9, 2021
Medical specialties, Vaccination, Vaccine, Virology, Adenoviridae, Medicine, Biology, Medical research, COVID-19 vaccines, Clinical trials

Avance Clinical Chief Scientific Officer Dr Gabriel Kremmidiotis said:

Key Points: 
  • Avance Clinical Chief Scientific Officer Dr Gabriel Kremmidiotis said:
    "The exciting aspect of the Tetherex product is the potential to vaccinate using a nasal spray.
  • According to Tetherex Pharmaceutical's announcement:
    Tetherex Pharmaceuticals has executed an exclusive worldwide license with Mayo Clinic for the development and commercialization of a novel single-cycle adenovirus vaccine platform.
  • The platform will be used to target multiple infectious diseases, beginning with a Phase 1 clinical study investigating a vaccine for COVID-19.
  • Avance Clinical is the largest full-service Australian CRO focussed on delivering quality clinical trials in Australia and New Zealand for international biotechs.

Trinity Health Announces COVID-19 Vaccine Requirement for All Colleagues

Retrieved on: 
Thursday, July 8, 2021
Medical specialties, Medicine, Trinity Health, Vaccine, Health sciences, Vaccines, COVID-19 vaccines, Clinical trials

LIVONIA, Mich., July 8, 2021 /PRNewswire/ --Trinity Health today announced, effective immediately, the national health system will require all colleagues, clinical staff, contractors, and those conducting business in its health care facilities to be vaccinated against COVID-19.

Key Points: 
  • LIVONIA, Mich., July 8, 2021 /PRNewswire/ --Trinity Health today announced, effective immediately, the national health system will require all colleagues, clinical staff, contractors, and those conducting business in its health care facilities to be vaccinated against COVID-19.
  • Since December 2020,when the U.S. Food and Drug Administration approved the first vaccine for Emergency Use Authorization, Trinity Health has strongly encouraged vaccination for all colleagues and within the communities its various Health Ministries serve.
  • To date, the health system estimates nearly 75% of Trinity Health employees have already received at least one dose of the vaccineand it now looks to close the gap with this new requirement.
  • "Over the last year, Trinity Health has counted our own colleagues and patients in the too-high coronavirus death toll.

Akston Biosciences Announces Positive Phase I Data for Second-Generation COVID-19 Vaccine Candidate

Retrieved on: 
Thursday, July 8, 2021
Health, Infectious diseases, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medical research, COVID-19 vaccine, Health sciences, Medicine, COVID-19 vaccines, Articles, Clinical trials, AKS-452, Akston Biosciences, TRACER, University Medical Center Groningen, AKS-452, AKSTON BIOSCIENCES, TRACER, UNIVERSITY MEDICAL CENTER GRONINGEN

Today, Akston Biosciences Corporation , a developer of new classes of biologic therapeutics, announced positive results from a 60-subject, open-label, Phase I trial of AKS-452, its protein subunit, room temperature stable, COVID-19 vaccine candidate.

Key Points: 
  • Today, Akston Biosciences Corporation , a developer of new classes of biologic therapeutics, announced positive results from a 60-subject, open-label, Phase I trial of AKS-452, its protein subunit, room temperature stable, COVID-19 vaccine candidate.
  • The trial will be managed by TRACER Europe B.V., a Contract Research Organization (CRO) specializing in fast-track clinical trials.
  • The results are very encouraging, showing limited side-effects, comparable to current registered anti-COVID-19 vaccines, over all dosing-cohorts, said Schelto Kruijff, M.D.
  • The study gives us even more confidence that AKS-452 is a vaccine for everywhere and everyone in the world.

PharmaJet Partner Zydus Cadila Seeks EUA on World’s First Plasmid DNA COVID-19 Vaccine

Retrieved on: 
Wednesday, July 7, 2021
Infectious diseases, Biotechnology, Pharmaceutical, Health, Branches of biology, Virology, Gene delivery, Biology, Medical specialties, COVID-19 vaccines, Clinical trials, ZyCoV-D, Cadila Healthcare, Vaccine, Plasmid, XBRL

PharmaJet , the maker of innovative, needle-free injection technology, today announced that its partner Zydus Cadila has applied for Emergency Use Authorization (EUA) to the office of the Drug Controller General of India (DCGI) for its plasmid DNA Vaccine against COVID-19.

Key Points: 
  • PharmaJet , the maker of innovative, needle-free injection technology, today announced that its partner Zydus Cadila has applied for Emergency Use Authorization (EUA) to the office of the Drug Controller General of India (DCGI) for its plasmid DNA Vaccine against COVID-19.
  • The ZyCoV-D vaccine is the first ever plasmid DNA vaccine for human use and represents a key milestone in scientific innovation and technology advancement.
  • Chris Cappello, President and CEO, PharmaJet, said, We are pleased to be partnering with Zydus Cadila as they move forward with plans to commercialize the first ever DNA vaccine for COVID-19.
  • The PharmaJet Needle-free Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization.